Loading
  • Main Menu
Caribbean Public Health Agency
  • Login
  • Home
  • Who We Are
    • About
    • Role and Function
    • Structure and People
    • Government Orientation
    • Member States
    • FAQs
  • What We Do
    • Caribbean Regulatory System
    • Communicable Diseases
    • CR-FELTP
    • Data and Health Information
    • Environmental Health
    • Emergency Response
    • Laboratory Services
    • Medicines Quality Control
    • Monitoring and Evaluation
    • Networks
    • Non-Communicable Diseases
    • Nutrition
    • Traveller's Health/THP
    • Vector Borne Diseases
  • Financial Statements
    • 2023 Audited Financial Statements
    • 2022 Audited Financial Statements
    • 2021 Audited Financial Statements
    • 2020 Audited Financial Statements
    • 2019 Audited Financial Statements
    • 2018 Audited Financial Statements
    • 2017 Audited Financial Statements
    • 2016 Audited Financial Statements
  • More
    • CARPHA Foundation
    • CARPHA Projects
    • Digital Library
    • Forum
    • Health Days
    • Internship
      • Call for Interns - Virtual Internship Programme
    • Media
    • Publications and Databases
    • Partner With Us
    • Webinars
    • Work With Us
  • Contact Us
English
EnglishSpanishFrenchDutch
Caribbean Public Health Agency
  • Home
  • Who We Are
    • About
    • Role and Function
    • Structure and People
    • Government Orientation
    • Member States
    • FAQs
  • What We Do
    • Caribbean Regulatory System
    • Communicable Diseases
    • CR-FELTP
    • Data and Health Information
    • Environmental Health
    • Emergency Response
    • Laboratory Services
    • Medicines Quality Control
    • Monitoring and Evaluation
    • Networks
    • Non-Communicable Diseases
    • Nutrition
    • Traveller's Health/THP
    • Vector Borne Diseases
  • Financial Statements
    • 2023 Audited Financial Statements
    • 2022 Audited Financial Statements
    • 2021 Audited Financial Statements
    • 2020 Audited Financial Statements
    • 2019 Audited Financial Statements
    • 2018 Audited Financial Statements
    • 2017 Audited Financial Statements
    • 2016 Audited Financial Statements
  • More
    • CARPHA Foundation
    • CARPHA Projects
    • Digital Library
    • Forum
    • Health Days
    • Internship
      • Call for Interns - Virtual Internship Programme
    • Media
    • Publications and Databases
    • Partner With Us
    • Webinars
    • Work With Us
  • Contact Us

Sputum Specimens for TB Testing

Home
  • What We Do
  • Laboratory
  • Annex 1-SPECIMEN COLLECTION GUIDELINES
  • Sputum Specimens for TB Testing

Collection of TB Samples

CARPHA performs a PCR assay using the Xpert MTB/RIF test (for use with the Cepheid GeneXpert® System). This is a semi-quantitative nested real-time PCR in-vitro diagnostic test for:

  • 1) the detection of Mycobacterium tuberculosis complex DNA in extrapulmonary as well as sputum samples or concentrated sediments prepared from induced or expectorated sputa that are either acid-fast bacilli (AFB) smear positive or negative; and
  • 2) the detection of rifampicin resistance associated mutations of the rpoB gene in samples from patients at risk for rifampicin resistance.

The MTB/RIF test is intended for use with specimens from untreated patients for whom there is clinical suspicion of tuberculosis (TB). Use of Xpert MTB/RIF for detection of M. tuberculosis (MTB) or determination of rifampicin susceptibility has not been validated for patients who are receiving treatment for tuberculosis.

STEP ACTION
1
  • Select a sample container.
2
  • Instruct the patient to rinse his or her mouth with plain water twice before bringing up the sputum.
3
  • Open the lid of the sample container.
4
  • Have the patient inhale deeply 2-3 times.
  • Cough deeply from the chest, and then spit into the sputum container by bringing it closer to the mouth.
  • Care should be taken to avoid spoiling or soiling the soiling the outside of the container.
  • Secure the lid on the collection device.
5
  • Make sure the sputum sample is of good quality.
  • Check the sample for food particles, blood or substances that may inhibit PCR process.
  • The sample volume should be at least 1ml.

Handling and Support

  • Treat all sputum samples as potentially infectious material and use leak proof containers for sample collection and transportation.
  • Specimens should be held at 2°C- 8°C (The sample remains viable at this temperature for 4-10 days.)
  • Transport the sample to CARPHA at (2°C- 8°C)
  • Introduction
  • General Information
  • Specimen Collection Information
  • Testing in Special Circumstances
  • Laboratory Testing Services
  • Download PDF
  • Annex 1-SPECIMEN COLLECTION GUIDELINES
    • Blood
    • Respiratory Tract Samples
    • Cerebrospinal Fluid
    • Faecal Specimens
    • Eye Specimen
    • Samples from Skin Lesions
    • Urine Specimens
    • Sputum Specimens for TB Testing
  • Annex 2 - GUIDELINES FOR PREPARATION, PACKING AND SHIPPING SPECIMENS
  • Annex 3 - Laboratory Investigation Form
  • Annex 4 - CARICOM Invoice
  • Annex 5 - Customer Feedback Form

CARPHA HEAD OFFICE

  • 16-18 Jamaica Blvd,
    Federation Park,
    Port of Spain,
    Trinidad & Tobago
  • (+868) 299-0820
    (+868) 299-0895
    (+868) 622-4261
  • postmaster@carpha.org

CARPHA JAMAICA

  • Hope Gardens,
    Kingston 6,
    Jamaica
  • (+876) 977-3540
    (+876) 702-4235

CARPHA ST. LUCIA

  • P.O. Box 1111,
    The Morne, Castries,
    Saint Lucia
  • (+758) 452-2501
    (+758) 452-1087
  • (+758) 453-2721

Email Us

  • *
  • *
  • *
  • *

Copyright 2022 by The Caribbean Public Health Agency

  • Back to top